BioSpace News Archive

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced the closing of its previously announced $30 million private placement to ten accredited investors.

Life Biosciences, a pioneering life sciences company developing therapeutics that target the biology of aging, today announced translational research funding from the Alzheimer’s Drug Discovery Foundation (ADDF) to support the development of chaperone-mediated autophagy (CMA) activators for the treatment of Alzheimer’s disease and other neurodegenerative diseases.

QuVa Pharma, Inc., a leading national 503B outsourcing services company to U.S. hospitals, and its parent company, QuVa Pharma Holdings, Inc (both, “QuVa Pharma”) have today announced the appointment of Talha Ashraf as an independent external director.

Nanocan Therapeutics Corporation (Nanocan), a clinical stage biotechnology company developing innovative cancer treatments, announced the appointment of Dr. Elizabeth Charlotte Moser, as its Chief Scientific Officer and member of the company’s executive leadership team.

Nanowear, a leading hospital-at-home and remote diagnostic platform informed by proprietary cloth nanotechnology and AI, today announced that it received its third FDA 510(k) clearance and first software-only clearance as an end-to-end digital platform, illustrating unique capabilities available to enterprise customer channels across a broad spectrum of diagnostic and monitoring verticals.

First use of a nanotechnology enhanced pedicle screw with label claims to increase and accelerate human osteoblast and mesenchymal stem cell calcified extracellular matrix production in vitro

Camber Spine has announced it will be featuring presentations on the Oblique Lateral Interbody Fusion Surgery (OLIF) technique at the North American Spine Society 36th Annual Meeting in Boston this week.

AB Science SA (Euronext - FR0010557264 - AB) today announced that a new clinical trial with masitinib in patients with symptomatic mild and moderate COVID-19 has been approved by the Regulatory Authorities of Russia and South Africa. Study AB21002, the second Phase 2 study of masitinib in COVID-19.

Kintara Therapeutics, Inc. announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rules, with several healthcare-focused institutional investors of 12,000,000 shares of its common stock and warrants to purchase up to an aggregate of 12,000,000 shares of common stock, at a combined offering price of $1.25 per share and associated warrant.

BTG Specialty Pharmaceuticals announced that Ohara Pharmaceutical Co., Ltd. has obtained marketing authorization for glucarpidase from Japan’s Ministry of Health, Labour and Welfare as a therapeutic agent for “detoxication in case of delayed methotrexate elimination with methotrexate-leucovorin rescue therapy,” on September 28, 2021.